Rapoport, Bernardo LeonArani, Ramin B.Mathieson, NicolaKrendyukov, Andriy2019-11-142019-11-142019-05Rapoport, B., Arani, R.B., Mathieson, N. et al. 2019, 'Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer', Future Oncology, vol. 15, no. 18, pp. 2163-2174.1479-6694 (print)1744-8301 (online)10.2217/fon-2018-086http://hdl.handle.net/2263/72288AIM : This meta-analysis compared incidence of grade 3-4 neutropenia with ALK inhibitors versus chemotherapy in patients with non-small-cell lung cancer. MATERIALS AND METHODS : PubMed/MEDLINE was searched to identify Phase II and III randomized clinical trials published up to 25 October 2018. Summary incidence, relative risk and corresponding 95% CIs were calculated for grade 3-4 neutropenia. RESULTS : Five randomized clinical trials were included. Relative risk (95% CI) of developing grade 3-4 neutropenia with ALK inhibitor versus chemotherapy was 0.27 (0.07-1.06). Probabilities of developing grade 3-4 neutropenia were 6.56 and 14.19%, respectively; no significant difference was found. CONCLUSION : In patients with non-small-cell lung cancer, incidence of grade 3-4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy.en© 2019 BL Rapoport, RB Arani, N Mathieson, A Krendyuko. This article is published open access.AlectinibALK inhibitorAnaplastic lymphoma kinaseCeritinibChemotherapyCrizotinibNeutropeniaNon-small-cell lung cancerTargeted therapyNon-small-cell lung carcinoma (NSCLC)Anaplastic lymphoma kinase (ALK)Article